Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 1Hypertension 1Dyspnea 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 18Trastuzumab 16Paclitaxel 15Taxes 11Doxorubicin 11Radiotherapy 7Lapatinib 6Albumin-Bound Paclitaxel 6Vorinostat 5Tamoxifen 5Docetaxel 5Carboplatin 5Capecitabine 5Bevacizumab 5Radiation 4Letrozole 4Immunohistochemistry 4Anastrozole 4sargramostim 3pegfilgrastim 3exemestane 3Magnetic Resonance Spectroscopy 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Granulocyte Colony-Stimulating Factor 3Fluorodeoxyglucose F18 3Flow Cytometry 3Filgrastim 3Chemotherapy, Adjuvant 3saponin QA-21V1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms, Male × Lisinopril × Clear all
NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡